Clinical Trials Browser

Phase 2 × Hereditary Sensory and Autonomic Neuropathies × 1 year × Clear all

NCT06433219 2026-06-03

Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

Phase 2 Active not recruiting

Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms

NCT05010031 2026-05-11

A Study of Reduced-dose Radiation in People With Metastatic Tumors With a Genetic Change

Phase 2 Recruiting

Neoplasm Metastasis, Hereditary Sensory and Autonomic Neuropathies

NCT07522697 2026-04-13

MITO END-4

Phase 2 Not yet recruiting

Hereditary Sensory and Autonomic Neuropathies, Endometrial Neoplasms

NCT03678883 2026-04-03

9-ING-41 in Patients With Advanced Cancers

Phase 2 Active not recruiting

BreastCNSGastrointestinalGenitourinaryLymphoidOther hematologic neoplasmSarcomaThoracic

Bone Neoplasms, Breast Neoplasms, Glioma, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Leukemia-Lymphoma, Adult T-Cell

NCT03056755 2026-01-13

BYLieve

Phase 2 Completed

383 enrolled 16 charts

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies

NCT05054725 2026-01-06

Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies

Phase 2 Completed

47 enrolled 17 charts

Bronchial Neoplasms, Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Respiratory Tract Diseases, Respiratory Tract Neoplasms

NCT06463028 2025-12-24

Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer

Phase 2 Recruiting

Genital Diseases, Hereditary Sensory and Autonomic Neuropathies, Endometrial Neoplasms, Carcinoma, Endometrioid

NCT04564027 2025-08-29

A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer

Phase 2 Completed

54 enrolled 16 charts

Hereditary Sensory and Autonomic Neuropathies

NCT04038502 2025-08-20

COBRA

Phase 2 Recruiting

Classical hematologyGenitourinary

Fanconi Anemia, Complementation Group N, Fanconi Anemia, Complementation Group D1, Hereditary Sensory and Autonomic Neuropathies, Prostatic Neoplasms